Drug
Bmn 165
Bmn 165: highest development phase Phase 2, developed by BioMarin Pharmaceutical. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- BioMarin Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| BMN 165 (rAvPAL-PEG) NCT01560286 | Phase 2 | Phenylketonuria |
Latest
No recent events.
Follow Bmn 165 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.